Casdatifan in moderate liver impairment
Treatments studied
Part of Digestive system clinical trials.
This study looks at how a new drug, casdatifan, is processed in the body in people with moderate liver problems compared to healthy people. Understanding this helps doctors decide if the drug is safe and how to dose it for patients with liver issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and have had a vasectomy.
- Your BMI must be between 18 and 42, and you must weigh at least 45 kg.
- You must either have moderate liver problems (Child-Pugh Class B) or be a healthy volunteer with no significant medical conditions.
- You cannot have Gilbert's syndrome.
- If you have liver problems, they must be stable for at least 2 months and not getting worse.
- If you have liver problems, you cannot have active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study tests how a new drug (AZD4144) is processed by the body in people with different levels of liver function. It aims to see if the drug is safe and how the liver affects its levels, which may help guide future dosing for patients with liver problems.
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.